|
1
|
Siegel RL, Fedewa SA, Miller KD,
Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2015. CA Cancer J Clin.
65:457–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Power L, Lefas G, Lambert P, Kim D,
Evaniuk D, Lotocki R, Dean E, Nachtigal MW and Altman AD: Hormone
use after nonserous epithelial ovarian cancer: Overall and
disease-free survival. Obstet Gynecol. 127:837–847. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pradjatmo H and Pradjatmo H: Impact of
preoperative serum levels of CA 125 on epithelial ovarian cancer
survival. Asian Pac J Cancer Prev. 17:1881–1886. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu CF, Liu SY, Min XY, Ji YY, Wang N, Liu
D, Ma N, Li ZF and Li K: The prognostic value of CXCR4 in ovarian
cancer: A meta-analysis. PLoS One. 9:e926292014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siddiqui WA, Ahad A and Ahsan H: The
mystery of BCL2 family: Bcl-2 proteins and apoptosis: An update.
Arch Toxicol. 89:289–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kontos CK, Christodoulou MI and Scorilas
A: Apoptosis-related BCL2-family members: Key players in
chemotherapy. Anticancer Agents Med Chem. 14:353–374. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shamas-Din A, Brahmbhatt H, Leber B and
Andrews DW: BH3-only proteins: Orchestrators of apoptosis. Biochim
Biophys Acta. 1813:508–520. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moldoveanu T, Follis AV, Kriwacki RW and
Green DR: Many players in BCL-2 family affairs. Trends Biochem Sci.
39:101–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thomadaki H and Scorilas A: BCL2 family of
apoptosis-related genes: Functions and clinical implications in
cancer. Crit Rev Clin Lab Sci. 43:1–67. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Frenzel A, Labi V, Chmelewskij W, Ploner
C, Geley S, Fiegl H, Tzankov A and Villunger A: Suppression of
B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad. Blood.
115:995–1005. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang R, Kang Y, Löhr CV, Fischer KA,
Bradford CS, Johnson G, Dashwood WM, Williams DE, Ho E and Dashwood
RH: Reciprocal regulation of BMF and BIRC5 (Survivin) linked to
Eomes overexpression in colorectal cancer. Cancer Lett.
381:341–348. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kutuk O and Letai A: Displacement of Bim
by Bmf and Puma rather than increase in Bim level mediates
paclitaxel-induced apoptosis in breast cancer cells. Cell Death
Differ. 17:1624–1635. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li D, Xu D, Xu Y, Chen L, Li C, Dai X,
Zhang L and Zheng L: MicroRNA-141-3p targets DAPK1 and inhibits
apoptosis in rat ovarian granulosa cells. Cell Biochem Funct.
35:197–201. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu H, Pan Y, Han X, Liu J and Li R:
MicroRNA-216a promotes the metastasis and epithelial-mesenchymal
transition of ovarian cancer by suppressing the PTEN/AKT pathway.
Onco Targets Ther. 10:2701–2709. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu K and Liang M: Upregulated microRNA-224
promotes ovarian cancer cell proliferation by targeting KLLN. In
Vitro Cell Dev Biol Anim. 53:149–156. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
PLOS ONE Editors: Retraction: miR-221
promotes tumorigenesis in human triple negative breast cancer
cells. PLoS One. 12:e01758692017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu Q, Li P, Chen X, Zong L, Jiang Z, Nan
L, Lei J, Duan W, Zhang D, Li X, et al: miR-221/222 induces
pancreatic cancer progression through the regulation of matrix
metalloproteinases. Oncotarget. 6:14153–14164. 2015.PubMed/NCBI
|
|
18
|
Gordanpour A, Stanimirovic A, Nam RK,
Moreno CS, Sherman C, Sugar L and Seth A: miR-221 Is down-regulated
in TMPRSS2: ERG fusion-positive prostate cancer. Anticancer Res.
31:403–410. 2011.PubMed/NCBI
|
|
19
|
Yang X, Yang Y, Gan R, Zhao L, Li W, Zhou
H, Wang X, Lu J and Meng QH: Down-regulation of mir-221 and mir-222
restrain prostate cancer cell proliferation and migration that is
partly mediated by activation of SIRT1. PLoS One. 9:e988332014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamashita R, Sato M, Kakumu T, Hase T,
Yogo N, Maruyama E, Sekido Y, Kondo M and Hasegawa Y: Growth
inhibitory effects of miR-221 and miR-222 in non-small cell lung
cancer cells. Cancer Med. 4:551–564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Li Q, Huang H, Li Y, Li L, Hou W and
You Z: Overexpression of miRNA-221 promotes cell proliferation by
targeting the apoptotic protease activating factor-1 and indicates
a poor prognosis in ovarian cancer. Int J Oncol. 2017.
|
|
22
|
Hong F, Li Y, Xu Y and Zhu L: Prognostic
significance of serum microRNA-221 expression in human epithelial
ovarian cancer. J Int Med Res. 41:64–71. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bustin SA, Benes V, Garson JA, Hellemans
J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL,
et al: The miqe guidelines: Minimum information for publication of
quantitative real-time pcr experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dahiya N, Sherman-Baust CA, Wang TL,
Davidson B, Shih Ie M, Zhang Y, Wood W III, Becker KG and Morin PJ:
MicroRNA expression and identification of putative miRNA targets in
ovarian cancer. PLoS One. 3:e24362008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gadducci A, Sergiampietri C, Lanfredini N
and Guiggi I: Micro-RNAs and ovarian cancer: The state of art and
perspectives of clinical research. Gynecol Endocrinol. 30:266–271.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He XX, Guo AY, Xu CR, Chang Y, Xiang GY,
Gong J, Dan ZL, Tian DA, Liao JZ and Lin JS: Bioinformatics
analysis identifies miR-221 as a core regulator in hepatocellular
carcinoma and its silencing suppresses tumor properties. Oncology
Rep. 32:1200–1210. 2014. View Article : Google Scholar
|
|
27
|
Gramantieri L, Fornari F, Ferracin M,
Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L and
Negrini M: MicroRNA-221 targets Bmf in hepatocellular carcinoma and
correlates with tumor multifocality. Clin Cancer Res. 15:5073–5081.
2009. View Article : Google Scholar : PubMed/NCBI
|
